Drugdiscovery >> Drugs >> News
7473
Views
title
Astellas’ diarrhea drug - Irribow approved in Japan - drugdiscovery.com


Astellas Pharma announced the approval of the additional formulation of Irribow OD Tablets for treatment of diarrhea-predominant irritable bowel syndrome in Japan.
Read More >>


Tags: Irribow, Astellas, diarrhea, irritable bowel syndrome, approval - August 16, 2013
Related Articles
7325
Views
Novartis’ COPD treatments approved in EU and Japan Novartis’ COPD treatments approved in EU and Japan
Ultibro Breezhaler has been approved by the European Commission as a maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). Ultibro Inhalation Capsul Read More >>

Tags: Ultibro, COPD, drug, Novartis, approval, EU, Japan

5621
Views
Bayer’s Stivarga approved in Japan Bayer’s Stivarga approved in Japan
Stivarga (regorafenib) has been approved for the treatment of patients with gastrointestinal stromal tumor (GIST) who have progressed after prior systemic cancer therapy. This is the second indication Read More >>

Tags: Stivarga, regorafenib, Bayer, Japan, GIST, gastrintestinal stromal tumor, colorectal cancer, metastatic

3308
Views
Relvar Ellipta approved in Japan Relvar Ellipta approved in Japan
GlaxoSmithKline’s and Theravance’s drug Relvar Ellipta, has been approved in Japan for the treatment of bronchial asthma. Read More >>

Tags: Relvar Ellipta, bronchial asthma, treatment, Japan, GSK

5462
Views
Microbiome’s diabetes drug  NM504 might help eliminating diarrhea caused by metformin Microbiome’s diabetes drug NM504 might help eliminating diarrhea caused by metformin
A case report shows that co-administration of NM504 eliminated the dose-limiting diarrhea caused by metformin in a patient with newly-diagnosed type 2 diabetes and suggests a potentially important new Read More >>

Tags: Microbiome Therapeutics, metformin, type 2 diabetes, diarrhea, NM504

1117
Views
ASTAGRAF XL now available in U.S. pharmacies ASTAGRAF XL now available in U.S. pharmacies
Astelas’ ASTAGRAF XL, a once-daily oral tacrolimus formulation for the prophylaxis of organ rejection in adult kidney transplant patients is now available in the U.S. Read More >>

Tags: astagraf xl, astellas, prophylaxis, organ rejection, kidney, transplant

10375
Views
Another Sanofi MS drug approved in EU Another Sanofi MS drug approved in EU
After Aubagio, Lemtrada - another Sanofi’s drug for treatment of multiple sclerosis has been approved by the European Commission. Read More >>

Tags: multiple sclerosis, Europe, new drug, Aubagio, Lemtrada

14682
Views
How Drugs are Developed and Approved How Drugs are Developed and Approved
In the United States, all medications except natural remedies and supplements, must go through an approval process before they can be made available to people. The Food and Drug Administration (FDA) i Read More >>

Tags: FDA, CDER, drug safety

13407
Views
Bayer’s new hypertension drug to be approved by FDA Bayer’s new hypertension drug to be approved by FDA
The new drug worked well in clinical trials and is recommended for approval but at lower doses than those proposed by the company. Read More >>

Tags: Bayer, new drug, hypertension, pulmonary hypertension

8155
Views
Takeda's schizophrenia drug lurasidone approved in Swiss Takeda's schizophrenia drug lurasidone approved in Swiss
This is the first approval in Europe for lurasidone, which is already marketed as Latuda for schizophrenia and bipolar depression in the US and Canada. Read More >>

Tags: lurasidone, latuda, drug, schizophrenia, bipoloar disorder, Swiss, approval, Europe

11968
Views
New drug for treating myeloma approved in Europe New drug for treating myeloma approved in Europe
The European Commission has granted approval for Celgene’s drug pomalidomide for the treatment of relapsed and refractory multiple myeloma, in combination with dexamethasone. The marketing name of Read More >>

Tags: Celgene, pomalidomide, multiple myeloma,Imnovid,the European Commission approval

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013